Kiniksa Pharmaceuticals (KNSA)
(Delayed Data from NSDQ)
$25.44 USD
-0.28 (-1.09%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $25.44 0.00 (0.00%) 5:20 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
KNSA 25.44 -0.28(-1.09%)
Will KNSA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KNSA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KNSA
Wall Street Analysts Believe Kiniksa Pharmaceuticals (KNSA) Could Rally 30.11%: Here's is How to Trade
Zacks.com featured highlights include Kiniksa Pharmaceuticals, HNI, AudioEye, Balchem and The Gorman-Rupp
KNSA: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Stocks With Recent Price Strength in a Volatile Market
Best Momentum Stocks to Buy for August 1st
New Strong Buy Stocks for August 1st
Other News for KNSA
Roth MKM says Small-Cap Value reaches key technical support, lists 14 "bullish" stocks
Analysts Offer Insights on Healthcare Companies: Kiniksa Pharmaceuticals (KNSA), Repligen (RGEN) and Teva Pharmaceutical (TEVA)
Short Report: Reddit bears refresh bets ahead of earnings
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today